On Thursday, Shares of Century Aluminum Co (NASDAQ:CENX), gained 1.40% to $5.81.
Century Aluminum of Kentucky, a wholly-owned partner of Century Aluminum Company, declared the orderly curtailment of one potline at its Hawesville, Kentucky aluminum smelter, effective right away. Following the curtailment, Hawesville’s primary aluminum production will be about 60% of capacity. The plant was operating at about 80% capacity preceding to the curtailment. Century Aluminum of Kentucky formerly issued a notice of its intent to curtail its plant operations in their entirety startning on October 24, 2015, unless the current pricing environment substantially changes, and such notice remains in effect.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes.
Shares of Air Products & Chemicals, Inc. (NYSE:APD), inclined 0.25% to $139.03, during its last trading session.
Air Products, declared that its Board of Directors has approved the intention to fully separate its Materials Technologies business via a tax-free spin-off to its shareholders. The targeted completion of the Materials Technologies spin-off is before September 2016, subject to typical regulatory approvals. Air Products held a conference call on Thursday, September 17, 2015 at 8:00 a.m. ET.
This planned decision will allow Air Products’ Industrial Gases and the Materials Technologies businesses to leverage their respective critical competencies and enhance their competitive positions. The Company believes the result of the spin-off will be two best-in-class public companies with distinct business models, capital requirements and growth profiles. The spin-off decision was made after an extensive review examining the planned options for the Materials Technologies business by Air Products’ Board of Directors and administration.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments.
At the end of Thursday’s trade, Shares of Flextronics International Ltd. (NASDAQ:FLEX), gained 0.18% to $11.13.
Flextronics International Ltd., has reached a definitive agreement to acquire NEXTracker, a leader in smart solar tracking solutions. NEXTracker designs and manufactures one of the world’s most advanced single-axis photovoltaic (PV) trackers that orients PV panels to maximize energy output. The acquisition will augment the Flex Energy business and contribute to its more than $1 billion in sales, and is predictable to be accretive to Flex’s growth, margin, EPS and cash flow generation.
NEXTracker has achieved noteworthyindustry breakthroughs in smart and connected tracking solutions that deliver high performance and flexibility for solar power plants of all sizes. It delivers a cost-effective solution to maximize solar project returns for its range of global customers that comprise developers, energy procurement construction companies, and system owners of ground-mounted solar power plants.
Flextronics International Ltd. provides design, manufacturing, and supply chain services and solutions to original equipment manufacturers worldwide. The company offers innovation services, such as innovations labs for supporting customer design and product development services from early concept stages; collective innovation platform, an ecosystem of technology solutions; Lab IX startup accelerator program; centers of excellence solutions in critical areas; interconnect technology center for printed circuits; and CloudLabs that enables customers to accelerate a spectrum of cloud, converged infrastructure, and datacenter strategies.
Finally, Sangamo Biosciences, Inc. (NASDAQ:SGMO), ended its last trade with 1.32% gain, and closed at $7.68.
Sangamo BioSciences, declared unanimous approval by the National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) of a Phase 1 study protocol for a ZFP Therapeutic as a potential curative therapy for hemophilia B. The Factor IX program will be the first clinical study of in vivo genome editing and the first therapeutic application of Sangamo’s In Vivo Protein Replacement Platform (IVPRP).
Sangamo anticipates to file an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) by the end of 2015 and, pending FDA clearance, plans to initiate a Phase 1 clinical trial in 2016. The Company recently reattained all of its hemophilia assets from Shire plc as a result of the amendment to the companies’ 2012 partnershipand license agreement.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
